Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Assets: 2017-2025

Historic Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $1.2 billion.

  • Crinetics Pharmaceuticals' Assets rose 27.59% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 27.59%. This contributed to the annual value of $1.4 billion for FY2024, which is 125.79% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Assets is $1.2 billion, which was down 7.25% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Assets registered a high of $1.4 billion during Q4 2024, and its lowest value of $163.6 million during Q1 2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Assets averaged around $910.6 million, with its median value being $937.4 million (2024).
  • Its Assets has fluctuated over the past 5 years, first plummeted by 30.46% in 2023, then spiked by 219.02% in 2024.
  • Crinetics Pharmaceuticals' Assets (Quarterly) stood at $351.0 million in 2021, then grew by 0.33% to $352.2 million in 2022, then spiked by 80.41% to $635.4 million in 2023, then surged by 125.79% to $1.4 billion in 2024, then climbed by 27.59% to $1.2 billion in 2025.
  • Its Assets was $1.2 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.4 billion in Q1 2025.